408 related articles for article (PubMed ID: 30604927)
1. Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review.
Ben Abdallah H; Fogh K; Bech R
Int Wound J; 2019 Apr; 16(2):511-521. PubMed ID: 30604927
[TBL] [Abstract][Full Text] [Related]
2. PAPA Syndrome: Challenges in Achieving Long-Term Remission.
Smajlović H; Prohić A
Acta Dermatovenerol Croat; 2023 Nov; 31(2):106-109. PubMed ID: 38006373
[TBL] [Abstract][Full Text] [Related]
3. Successful switching treatment of adalimumab for refractory pyoderma gangrenosum in a patient with rheumatoid arthritis with prior use of tumour necrosis factor inhibitors: A case report and review of the literature.
Ohmura SI; Homma Y; Hanai S; Otsuki Y; Miyamoto T
Mod Rheumatol Case Rep; 2023 Jan; 7(1):9-13. PubMed ID: 35285489
[TBL] [Abstract][Full Text] [Related]
4. The role of anti-tumor necrosis factor-alpha therapy in Pyoderma gangrenosum associated with inflammatory bowel disease.
Reguiaï Z; Grange F
Am J Clin Dermatol; 2007; 8(2):67-77. PubMed ID: 17428111
[TBL] [Abstract][Full Text] [Related]
5. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor-α inhibitors for the treatment of pyoderma gangrenosum not associated with inflammatory bowel diseases: A multicenter retrospective study.
Rousset L; de Masson A; Begon E; Villani A; Battistella M; Rybojad M; Jachiet M; Bagot M; Bouaziz JD; Lepelletier C
J Am Acad Dermatol; 2019 Apr; 80(4):1141-1143. PubMed ID: 30342166
[No Abstract] [Full Text] [Related]
7. Pyoderma gangrenosum: clinical characteristics, associated diseases, and responses to treatment in a retrospective cohort study of 31 patients.
Vacas AS; Torre AC; Bollea-Garlatti ML; Warley F; Galimberti RL
Int J Dermatol; 2017 Apr; 56(4):386-391. PubMed ID: 28295267
[TBL] [Abstract][Full Text] [Related]
8. Direct Comparative Effectiveness Among 3 Anti-Tumor Necrosis Factor Biologics in a Real-Life Cohort of Patients With Rheumatoid Arthritis.
Santos-Moreno P; Sánchez G; Gómez D; Bello-Gualtero J; Castro C
J Clin Rheumatol; 2016 Mar; 22(2):57-62. PubMed ID: 26886438
[TBL] [Abstract][Full Text] [Related]
9. Comparison of continuation rates with three TNFα antagonists (adalimumab, infliximab, etanercept) in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: Retrospective 10-year study.
Batteux B; Devauchelle A; Boyard PL; Sejourné A; Fardellone P; Goëb V
Joint Bone Spine; 2016 Oct; 83(5):607-9. PubMed ID: 26919803
[No Abstract] [Full Text] [Related]
10. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety.
Alonso-Ruiz A; Pijoan JI; Ansuategui E; Urkaregi A; Calabozo M; Quintana A
BMC Musculoskelet Disord; 2008 Apr; 9():52. PubMed ID: 18419803
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory arthritis-associated pyoderma gangrenosum: a systematic review.
Sawka E; Zhou A; Latour E; Friedman M; Ortega-Loayza AG
Clin Rheumatol; 2021 Oct; 40(10):3963-3969. PubMed ID: 34002351
[TBL] [Abstract][Full Text] [Related]
12. Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis.
García-Lagunar MH; Gutiérrez-Cívicos MR; García-Simón MS; Conesa-Zamora P; Jimenez-Santos E; Cano-Vivar P; García-Márquez A; Muñoz-García I; Viney AC
Ann Pharmacother; 2017 May; 51(5):388-393. PubMed ID: 27920336
[TBL] [Abstract][Full Text] [Related]
13. Biologics and immunoglobulins in the treatment of pyoderma gangrenosum - analysis of 52 patients.
Herberger K; Dissemond J; Brüggestrat S; Sorbe C; Augustin M
J Dtsch Dermatol Ges; 2019 Jan; 17(1):32-41. PubMed ID: 30592563
[TBL] [Abstract][Full Text] [Related]
14. Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: results of a systematic review.
Fidder HH; Singendonk MM; van der Have M; Oldenburg B; van Oijen MG
World J Gastroenterol; 2013 Jul; 19(27):4344-50. PubMed ID: 23885145
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
[TBL] [Abstract][Full Text] [Related]
17. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis.
Gibellini L; De Biasi S; Bianchini E; Bartolomeo R; Fabiano A; Manfredini M; Ferrari F; Albertini G; Trenti T; Nasi M; Pinti M; Iannone A; Salvarani C; Cossarizza A; Pellacani G
PLoS One; 2016; 11(12):e0167757. PubMed ID: 27936119
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Three Assays to Quantify Infliximab, Adalimumab, and Etanercept Serum Concentrations.
van Bezooijen JS; Koch BC; van Doorn MB; Prens EP; van Gelder T; Schreurs MW
Ther Drug Monit; 2016 Aug; 38(4):432-8. PubMed ID: 27120178
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
20. Treatment of pyoderma gangrenosum with etanercept.
McGowan JW; Johnson CA; Lynn A
J Drugs Dermatol; 2004; 3(4):441-4. PubMed ID: 15303791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
